Pages

Pages

Saturday, 20 December 2014

WO2008059370A2

Example 11 : Λ/-(1-(1-(2-hvdroxyethvh-5-methyl-1H-pyrazol-4-vhethvh-2- (2,2.2-trifluoro-1.1 -dimethylethvOαuinoline-β-carboxamtde


Figure imgf000072_0002
To a solution of Example 10 (23 mg, 0.05 mmol) in THF (3 ml) was added LiBH4 powder (3.25 mg, 0.15 mmol) at rt, and the resulting mixture was heated at 65 0C, then MeOH (3 drops) was added and the resulting mixture was heated at the same temperature for 60 min. After being cooled to rt, the reaction mixture was quenched by addition of sat. NH4CI aq. and the aqueous layer was extracted with AcOEt 3 times. The combined organic extracts were washed with water and brine successively, dried over Na2SO4 and concentrated in vacuo. The crude material was purified by HPLC (column: MS C 30 x 50 mm, acetonitrile: 0.01 % NH3 aq =96:4 to 4:96 as eluent) to give the title compound as a white solid (16.6 mg, 77% yield). 1H NMR (300 MHz, DMSO-Of6) δ 1.50 (3H, d, J = 6.0 Hz), 1.71 (6H1 s), 2.26 (3H, s), 3.67 (2H, dd, J = 6.0, 12.0 Hz)1 4.03 (2H1 t, J = 6.0 Hz), 4.84 (1 H, t, J = 6.0 Hz)1 5.14-5.24 (1 H, m), 7.46 (1 H1 s), 7.87 (1 H1 d, J = 9.0 Hz)1 8.07 (1H1 d, J = 9.0 Hz), 8.19-8.23 (1 H1 m), 8.50-8.53 (2H1 m), 8.85 (1 H1 brd, J = 6.0 Hz). MS (ESI) m/z 433 (M - H)" , 435 (M + H)+.






DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE


Join me on Linkedin

View Anthony Melvin Crasto Ph.D's profile on LinkedIn

Join me on Facebook FACEBOOK
Join me on twitterFollow amcrasto on Twitter     
Join me on google plus Googleplus

 amcrasto@gmail.com






No comments:

Post a Comment